What it is
IGF-1 LR3 stands for Long Arginine 3 Insulin-like Growth Factor 1. It is a lab-made version of IGF-1, a hormone your liver already makes in response to growth hormone — the hormone that drives repair, muscle building, and fat burning. IGF-1 carries out most of growth hormone's work in the body.
The full peptide is 83 amino acids long, compared with 70 in natural IGF-1. Two changes were made: the amino acid at position 3 was swapped from glutamic acid to arginine, and 13 extra amino acids were added to one end.
Those changes matter because of what normally happens to IGF-1. Once released, almost all of it is grabbed by carrier proteins called IGF binding proteins. They ferry it around, limit how much is free to act, and cap its active life at roughly 12 to 15 hours. IGF-1 LR3 barely sticks to those carriers, so it circulates free and active. The result is about 3 times the potency of natural IGF-1 and a much longer active window of 20 to 30 hours.
The "insulin-like" part of the name is literal. It has some of the same effects as insulin and it does lower blood sugar, which is the main thing to plan around.
IGF-1 LR3 is not approved by the FDA for any medical use. The only approved use of direct IGF-1 is a rare genetic condition where growth hormone receptors do not work and the liver cannot convert growth hormone into IGF-1. It has been used in bodybuilding for decades and is banned by WADA under peptide hormones, growth factors, and related substances.
It arrives as a dry powder in a 1 mg vial. Unlike most peptides, it is mixed with 0.6% acetic acid solution rather than bacteriostatic water, then injected under the skin or into muscle.
IGF-1 LR3 is an 83-amino-acid analogue of insulin-like growth factor 1, the principal mediator of growth hormone's peripheral effects, against 70 amino acids in the native hormone. Two modifications define it: substitution of arginine for glutamic acid at position 3, and a 13-amino-acid N-terminal extension.
Native hepatic IGF-1 is almost entirely sequestered by IGF binding proteins, which chaperone it through circulation, regulate receptor availability, and limit half-life to roughly 12 to 15 hours. The LR3 modifications confer extremely low IGFBP affinity, principally for IGFBP-3, so the peptide circulates largely unbound. Potency rises to approximately 3 times that of native IGF-1 and half-life extends to 20 to 30 hours.
The insulin-like designation is mechanistic: IGF-1 exerts insulin-like actions in peripheral tissue and lowers blood glucose. Tomas et al. (1997) showed in pigs and marmoset monkeys that IGF-1 variants with poor binding protein affinity, including LR3-IGF-1, were 2 to 3 times more potent than native IGF-1 at lowering blood glucose and produced 4 to 8 times greater cumulative hypoglycaemic effect over four hours.
IGF-1 sits within the growth-factor family alongside epidermal, platelet-derived, and nerve growth factors, but is distinguished as the only one with well-characterised endocrine action in humans.
IGF-1 LR3 holds no FDA approval. The sole approved indication for direct IGF-1 is the rare genetic condition in which GH receptor signalling fails and the liver cannot convert GH into IGF-1. It is prohibited by WADA under peptide hormones, growth factors, and related substances.
Supplied as a 1 mg lyophilised vial. Reconstitution requires 0.6% acetic acid solution, not bacteriostatic water, whose benzyl alcohol degrades the peptide structure within 24 to 48 hours. Subcutaneous or intramuscular administration.
How it works
IGF-1 LR3 locks onto the IGF-1 receptor, a docking point found on cells all over the body. Once it docks, the receptor switches on and sets off two chains of signals inside the cell.
The first chain is called PI3K-Akt-mTOR. Think of it as the growth and repair command centre. When it fires, cells build more protein, take up more glucose, survive longer, and stop breaking down the protein they already hold. This is the main driver of muscle gain.
The second chain is called MAPK. Where the first chain builds, this one multiplies — it drives cells to divide and specialise.
Muscle grows two ways here. Hypertrophy means existing muscle fibres get bigger. Hyperplasia means satellite cells — the muscle's own stem cells — are switched on, multiply, and either fuse into existing fibres to add new nuclei or form new fibres. Research suggests about half of IGF-1's muscle-growth effect depends on satellite cells, with the other half coming from direct effects on fibres already there. That satellite cell part is what sets it apart from most other muscle-building tools.
Because it barely binds to carrier proteins, it stays active for 20 to 30 hours, so one dose works across the whole body all day.
This is very different from growth hormone boosters such as CJC-1295 and Ipamorelin. Those work upstream: they ask your pituitary to release your own growth hormone, which your liver turns into IGF-1. IGF-1 LR3 skips all of that and hits the receptor directly. That makes it more predictable, but it also puts it outside your body's normal checks.
There is a catch. When your IGF-1 level rises, your brain releases somatostatin, which blocks the pituitary from answering growth hormone signals. This is why the boosters and IGF-1 LR3 cancel each other out.
IGF-1 LR3 binds and activates the IGF-1 receptor, a receptor tyrosine kinase expressed broadly across tissue. Ligand binding triggers receptor autophosphorylation and initiates two principal cascades.
The PI3K-Akt-mTOR arm drives protein synthesis, promotes cell survival, enhances glucose uptake into myocytes, and suppresses proteolysis. Yoshida and Delafontaine (2020) confirmed that IGF-1 raises skeletal muscle protein synthesis via PI3K-Akt-mTOR and PI3K-Akt-GSK3 beta signalling while suppressing breakdown by blocking expression of the E3 ubiquitin ligases that drive proteasome-mediated degradation. The MAPK arm drives proliferation and differentiation.
The combination produces both hypertrophy and hyperplasia. Satellite cell activation adds myonuclei to existing fibres and can generate new fibres. Barton-Davis et al. (1999) disabled satellite cell function with gamma radiation in mice and cut the IGF-1 growth response roughly in half, establishing that approximately 50 per cent of the hypertrophic effect is satellite-cell dependent.
Fryburg (1994) showed in healthy humans that intra-arterial IGF-1 infusion increased forearm muscle protein synthesis by 49 to 74 per cent and decreased protein degradation by approximately 45 per cent at higher doses, with blood flow increasing 75 to 213 per cent depending on dose, concluding that IGF-1 exerts both GH-like and insulin-like actions on human muscle protein metabolism.
Low IGFBP affinity keeps the peptide in circulation for 20 to 30 hours rather than being sequestered and cleared, giving sustained systemic exposure per dose.
The pharmacology diverges fundamentally from secretagogues. CJC-1295 and Ipamorelin act upstream on the pituitary, preserving hepatic conversion and the endogenous feedback loop. IGF-1 LR3 bypasses pituitary and liver entirely, acting at the receptor directly — more predictable, but outside physiological restraint.
Rising circulating IGF-1 provokes hypothalamic somatostatin release, which blocks pituitary responsiveness to GH-releasing signals. Research showed GHRH pathway compounds including CJC-1295, Tesamorelin, and Sermorelin were inhibited by 86 per cent, and ghrelin pathway compounds such as Ipamorelin were blunted by about 32 per cent, after exogenous GH injection.
What it does
Muscle: it is one of the fastest-acting muscle-building compounds studied. It makes existing fibres larger by raising protein building and shutting down protein breakdown, and it wakes up satellite cells, the repair cells sitting alongside muscle fibres, which can add new nuclei or new fibres.
Recovery: the same satellite cell process that grows muscle also repairs fibres damaged by training. Users report faster turnaround between sessions and better healing of minor training niggles.
Body composition: higher IGF-1 is linked with better nutrient partitioning, meaning more of what you eat goes toward muscle rather than fat. Its insulin-like effects push glucose into muscle cells, which helps refill glycogen around training. It also encourages fat breakdown and discourages new fat stores from forming.
Blood sugar: it lowers blood sugar, and it can do so quickly. This is the effect to plan meals around.
Bone and connective tissue: it stimulates bone-building cells and supports repair of tendons and joints, which matters under heavy training loads.
Growth hormone: it carries out and manages most of growth hormone's work in the body.
Inflammation, appetite, and energy: it reduces inflammation, tends to lower hunger and food cravings, raises metabolic rate, and lifts overall energy.
Cells in general: it tells cells to grow. That is the point of the compound and also the reason for caution at high doses over long periods.
Skeletal muscle: dual-mechanism growth. Hypertrophy through elevated protein synthesis and positive nitrogen balance, plus hyperplasia through satellite cell proliferation adding myonuclei and potentially new fibres. Proteolysis is simultaneously suppressed via E3 ubiquitin ligase inhibition.
Recovery: satellite cell activation underpins repair of exercise- and injury-induced fibre damage, with faster inter-session recovery reported in practice.
Body composition: elevated IGF-1 is associated with improved nutrient partitioning, directing calories toward muscle rather than adipose storage. Insulin-like activity enhances glucose uptake into myocytes, supporting glycogen replenishment around training. Promotes lipolysis and limits accumulation of new adipocyte stores.
Glycaemic: lowers blood glucose, rapidly and substantially. Hypoglycaemia is the defining acute pharmacological liability.
Skeletal and connective tissue: stimulates bone formation through direct osteoblast effects and supports connective tissue repair, relevant under cumulative tendon and joint loading.
Somatotropic: mediates and manages the peripheral effects of GH; simultaneously triggers hypothalamic somatostatin release as negative feedback.
Metabolic and other: reduces systemic inflammation, upregulates metabolic rate, reduces hunger and food cravings — the opposite direction from the ghrelin-mimetic secretagogues — and increases overall energy. Increases renal sodium reabsorption, which drives fluid retention.
Proliferative: broad mitogenic signalling via the MAPK arm. Conlon et al. (1995) showed Long R3 IGF-1 infusion in guinea pigs significantly increased the weight of adrenals, gut, kidneys, and spleen relative to controls, which is the mechanistic basis of the organ-overgrowth concern at sustained supraphysiological exposure. Clark et al. (2026) found IGF-1 LR3 delivered by hydrogel filler for volumetric muscle loss in rats increased muscle weight at high doses but produced no measurable improvement in function, fibre size, or fibre count — a reminder that more IGF-1 does not automatically mean more functional muscle.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Builds muscle two ways at once: bigger existing fibres, plus new satellite cells that add growth capacity you did not have before.Animal or lab only
- Raises protein building and blocks protein breakdown at the same time.Animal or lab only
- Speeds repair of muscle damaged by training or minor injury, so recovery between sessions improves.Animal or lab only
- Improves nutrient partitioning — more of what you eat goes to muscle rather than fat.Animal or lab only
- Pushes glucose into muscle cells, helping refill glycogen around training.Animal or lab only
- Supports bone formation and repair of tendons and connective tissue.Animal or lab only
- Carries out and manages growth hormone's effects in the body.Animal or lab only
- Reduces inflammation.Animal or lab only
- Breaks down body fat and discourages new fat stores from forming.Anecdotal
- Speeds up metabolism and boosts overall energy.Anecdotal
- Reduces hunger and food cravings.Anecdotal
- Users commonly report better fullness and stronger pumps in training within the first week or two.Anecdotal
- Runs alongside testosterone replacement therapy without conflict — different pathways, no interaction concerns, and users report greater strength, better endurance, and shorter recovery times from the pairing.Anecdotal
- Dual-mechanism hypertrophy: increased protein synthesis with positive nitrogen balance alongside satellite cell activation adding myonuclei and potentially new fibres.Animal or lab only
- Suppresses proteolysis by blocking E3 ubiquitin ligase expression, per Yoshida and Delafontaine (2020).Animal or lab only
- Accelerates tissue repair and regeneration through the same satellite cell pathway that drives growth.Animal or lab only
- Improves nutrient partitioning toward lean tissue rather than adipose storage.Animal or lab only
- Enhances myocyte glucose uptake, supporting peri-training glycogen replenishment.Animal or lab only
- Stimulates osteoblast-mediated bone formation and connective tissue repair.Animal or lab only
- Mediates and manages the peripheral effects of GH without requiring pituitary or hepatic participation, making response more predictable than with secretagogues.Animal or lab only
- Reduces systemic inflammation.Animal or lab only
- Promotes lipolysis and prevents accumulation of new adipocyte stores.Anecdotal
- Upregulates metabolic rate and increases overall energy.Anecdotal
- Reduces hunger and food cravings.Anecdotal
- Enhanced intramuscular fullness and training pump reported within the first 1 to 2 weeks.Anecdotal
- Compatible with TRT: no interaction concerns, distinct pathways, with increased strength, better endurance, accelerated gains, and shorter recovery reported in practice.Anecdotal
What to expect
No published clinical data establishes timelines for IGF-1 LR3 in healthy people using injection protocols. Everything below comes from user reports, not trials, so treat it as anecdotal.
Weeks 1 to 2: most people notice fuller muscles and better pumps during training. Some water retention is common early because IGF-1 LR3 makes the kidneys hold on to more sodium, which pulls water with it. This is cosmetic and goes away when you come off.
Weeks 3 to 4: this is when visible changes in body composition and clearly better recovery between sessions tend to show up. People carrying less body fat usually notice results sooner.
End of a 4 to 6 week cycle: users commonly report 3 to 8 pounds of lean tissue gain, with forum reports ranging up to 10 pounds at doses of 40 to 80 mcg daily. Results vary a lot — some people report dramatic changes, others very little.
The cycle ends at 4 to 6 weeks for a reason. IGF-1 receptors become less responsive with constant exposure; they get pulled into the cell and broken down, so the same dose does less. Take the time off and they recover.
The side effects people mention most are mild water retention and bloating, and low blood sugar symptoms such as shakiness, sweating, and light-headedness — usually when a dose is taken without enough carbohydrate. Joint pain and mild headaches come up less often. Some users describe tiredness during the cycle.
No published clinical data establishes timelines for IGF-1 LR3 in healthy humans on subcutaneous or intramuscular protocols. What follows is aggregated user report, not trial data.
Weeks 1 to 2: increased intramuscular fullness and enhanced training pump. Early water retention is common, driven by increased renal sodium reabsorption and consequent fluid shift. It is cosmetic and resolves on cessation. Restricting water or sodium worsens it.
Weeks 3 to 4: visible body composition change and improved inter-session recovery. Leaner individuals report noticing change sooner.
By the close of a 4 to 6 week cycle, 3 to 8 pounds of lean tissue gain is commonly reported, with bodybuilding forum reports of 3 to 10 pounds at 40 to 80 mcg daily. Response variance is wide, with some reporting dramatic results and others minimal effect. Higher doses correlate with greater reported gains and more pronounced side effects.
The 4 to 6 week ceiling reflects IGF-1 receptor desensitisation. Prolonged stimulation drives downregulation through receptor internalisation and degradation, reducing responsiveness. The off period restores receptor density.
Reported adverse effects cluster around mild water retention and bloating, and hypoglycaemic symptoms — shakiness, sweating, light-headedness — particularly when dosing without adequate carbohydrate intake. Joint pain and mild headache appear less frequently. Lethargy and fatigue during the cycle are described by some users.
A recurring practical theme is reconstitution error: users mixing with bacteriostatic water and losing the peptide to benzyl alcohol degradation within 24 to 48 hours.
Reconstitution and dosing
There are no published dose-finding studies for IGF-1 LR3 in healthy people using injection. The animal research used infusion protocols, and the one approved use of natural IGF-1 is dosed differently. The protocols below come from user reports and clinical practice patterns, not trials.
Mixing. The vial holds 1 mg of dry powder. Do not use bacteriostatic water — the benzyl alcohol in it breaks the peptide down within 24 to 48 hours. Use 0.6% acetic acid solution, bought separately, and add 1 mL. That gives 100 mcg per 10 units on an insulin syringe. Keep the vial in the fridge at 2 to 8 C and use it within 28 days.
Dose. 40 to 80 mcg daily, once a day. Inject under the skin or into muscle — both work. Injecting into the muscle you just trained gives a higher local concentration, which some users prefer. Alternating (under the skin on rest days, into muscle on training days) is fine.
Timing. Post-workout is the usual choice, within 15 to 30 minutes of finishing. Training leaves muscle primed to take up nutrients. Always have fast-acting carbohydrate and protein ready, and eat them shortly after injecting. This blunts the blood sugar drop and supports the muscle-building effect at the same time.
If you are new to it. Week 1: 20 to 40 mcg daily to see how you tolerate it. Weeks 2 to 4: 40 to 60 mcg daily. Weeks 5 to 6: hold or taper down. Then take at least 4 weeks off before repeating.
Cycling. 4 to 6 weeks on, 4 to 6 weeks off. Going past 6 weeks raises the risk of receptors switching off and of insulin resistance. The break lets them recover.
Do not combine it with growth hormone boosters such as CJC-1295, Ipamorelin, Tesamorelin, Sermorelin, or MK-677. The raised IGF-1 blocks them from working. Run them one after the other instead. Combining with insulin is dangerous.
No published dose-finding studies exist for IGF-1 LR3 in healthy humans on subcutaneous or intramuscular protocols. Animal work used infusion at varying concentrations, and the single approved indication for native IGF-1 (Laron syndrome) is dosed differently. The following reflects user reports and clinical practice patterns.
Reconstitution. 1 mg vial with 1 mL of 0.6% acetic acid solution, not bacteriostatic water. Benzyl alcohol degrades the peptide structure within 24 to 48 hours; the mildly acidic pH of acetic acid maintains structural stability through the full vial. Resulting concentration is 100 mcg per 10 units on an insulin syringe. Refrigerate at 2 to 8 C and use within 28 days.
Standard protocol. 40 to 80 mcg daily, once daily, subcutaneous or intramuscular. Intramuscular injection into the trained muscle gives localised concentration at target tissue; subcutaneous still delivers systemic benefit. Alternating subcutaneous on rest days and intramuscular on training days is workable.
Timing. Within 15 to 30 minutes post-training, capitalising on training stimulus and enhanced nutrient uptake. Fast-acting carbohydrate and protein should be available and consumed shortly after injection: this both mitigates hypoglycaemia risk and supports the anabolic environment.
Conservative entry. Week 1: 20 to 40 mcg daily to assess tolerance. Weeks 2 to 4: 40 to 60 mcg daily. Weeks 5 to 6: maintain or taper down. Minimum 4 weeks off before repeating.
Cycling is non-negotiable. 4 to 6 weeks on, 4 to 6 weeks off. Continuous use beyond 6 weeks increases the risk of receptor desensitisation and insulin resistance; receptors recover during the washout.
Hypoglycaemia is the principal acute risk. Fast-acting carbohydrate must be on hand at every dose.
Do not run concurrently with GH secretagogues — CJC-1295, Ipamorelin, Tesamorelin, Sermorelin, MK-677. Elevated IGF-1 triggers somatostatin, which blocks pituitary responsiveness; GHRH pathway compounds were inhibited by 86 per cent and ghrelin pathway compounds blunted by about 32 per cent. Sequence them: 4 to 6 weeks of LR3, at least 2 to 3 days off to let the feedback reverse, then a secretagogue phase. Concurrent insulin can produce severe, potentially fatal hypoglycaemia.
Standard, 1 mg vial
Mix with 1 mL (100 units) of bacteriostatic water.
1 mg/mL · 10 mcg per unit
Cycle: 4–6 weeks on, 4–6 weeks off · Frequency: 1×/day, subcutaneous or intramuscular, within 15–30 minutes after training
| When | Dose | Draw | How often |
|---|---|---|---|
| Starting | 40 mcg | 4 units | 1×/day post-workout |
| Full | 80 mcg | 8 units | 1×/day post-workout |
Alternative protocols
Alternative protocols reflect older community practice and are kept for reference.
Alternative, 1 mg vial
Reconstitute with 2.5 mL (250 units) of 0.6% acetic acid solution — not bacteriostatic water. Water alone permits premature degradation and loss of effect.
0.4 mg/mL · 4 mcg per unit
Cycle: 8 weeks, then a 4–8 week washout · Frequency: 1×/day, 7 days a week, within 30 minutes after training, with a carbohydrate and protein meal
| When | Dose | Draw | How often |
|---|---|---|---|
| Week 1 | 33 mcg | 8.25 units | 1×/day post-workout |
| Week 2 | 50 mcg | 12.5 units | 1×/day post-workout |
| Weeks 3–4 | 75 mcg | 18.75 units | 1×/day post-workout |
| Weeks 5–8 | 100 mcg | 25 units | 1×/day post-workout |
1 mg in 1 mL is 1 mg/mL, or 10 mcg per unit. Draw 4 units (0.04 mL) for 40 mcg.
Who should avoid it
- Do not use it if you have active cancer or a history of cancer. IGF-1 is a growth signal and it does not tell the difference between healthy tissue and a tumour.
- Do not use it if you have diabetes or any insulin-dependent condition, because the risk of severe low blood sugar is high.
- Do not use it if you have diabetic retinopathy (eye damage from diabetes).
- Do not use it if you are pregnant or breastfeeding.
- Use extreme caution if you have pre-diabetes or metabolic syndrome.
- Use extreme caution if you have a history of low blood sugar episodes.
- Use extreme caution if you have heart disease, because IGF-1 can affect growth of heart tissue.
- Use extreme caution with any condition that affects how growth is regulated in the body.
- Never combine it with insulin. Both drop blood sugar by different routes and together they can cause severe, potentially fatal hypoglycaemia.
- Oral diabetes medicines can have their blood-sugar-lowering effect amplified by IGF-1 LR3.
- Do not run it at the same time as growth hormone secretagogues such as CJC-1295, Ipamorelin, Tesamorelin, Sermorelin, or MK-677 — the raised IGF-1 blocks the signal they are trying to send.
- High doses over long periods can cause an irregular heartbeat, overabundant tissue growth (especially in the face), and acromegalic cardiomyopathy, which is enlargement and weakening of the heart.
- Keep the dose as low as possible for as long as possible, and only increase it if you need to.
- It is not approved by the FDA for any use in healthy people, and it is banned by WADA, so anyone who is drug tested in sport should not touch it.
- If you use it, check fasting blood glucose regularly, plus fasting insulin and serum IGF-1. Baseline IGF-1 of 120 to 160 ng/mL is the optimal range; above 300 ng/mL is where heart and cell-growth risks climb. Also watch for swelling, gut symptoms, joint pain, and carpal tunnel symptoms.
- Absolute contraindications: active malignancy or history of cancer, since IGF-1 is a mitogenic signal that does not discriminate between healthy and malignant tissue.
- Absolute contraindication: diabetes or insulin-dependent conditions, given the risk of severe hypoglycaemia.
- Absolute contraindication: diabetic retinopathy.
- Absolute contraindication: pregnancy or breastfeeding.
- Extreme caution: pre-diabetes or metabolic syndrome.
- Extreme caution: history of hypoglycaemia.
- Extreme caution: cardiovascular disease, as IGF-1 can affect cardiac tissue growth.
- Extreme caution: any condition affecting growth regulation.
- Insulin co-administration is extremely dangerous — additive glucose lowering by distinct mechanisms, potentially life-threatening hypoglycaemia. Not recommended outside highly supervised medical settings.
- Oral antidiabetic agents may be potentiated.
- GH secretagogues are functionally contraindicated as concurrent therapy: exogenous IGF-1 drives hypothalamic somatostatin release, and after exogenous GH injection GHRH-pathway compounds were inhibited by 86 percent and ghrelin-pathway compounds blunted by about 32 percent.
- High dose, long-term risks: cardiac arrhythmia, overabundant tissue growth (particularly facial), and acromegalic cardiomyopathy.
- Governing principle: lowest effective dose for the shortest necessary period, titrating only as required, with mandatory cycling to avoid receptor downregulation and insulin resistance.
- Not FDA approved for any indication outside Laron-type GH receptor insensitivity; prohibited by WADA under Peptide Hormones, Growth Factors, and Related Substances.
- Monitoring: fasting glucose (critical, checked regularly), fasting insulin, serum IGF-1 (optimal baseline 120 to 160 ng/mL; above 300 ng/mL is where cardiovascular and proliferative risk climbs), oedema, GI symptoms that may signal intestinal growth, and joint or carpal tunnel symptoms.
Side effects
- Low blood sugar is the main risk. Signs are shakiness, tremor, sweating, confusion, trouble concentrating, weakness, and a fast heartbeat. Always keep fast-acting carbohydrate to hand and eat carbs and protein around the injection.
- Water retention and bloating. IGF-1 LR3 makes the kidneys hold on to sodium, which pulls water with it. It is cosmetic and clears when you come off. Do not cut water or salt to fix it — that makes it worse.
- Joint and muscle pain.
- Headache.
- Fatigue or lethargy during the cycle.
- Nausea.
- Reaction where you inject — swelling, redness, and/or itching.
- Abdominal discomfort and bloating.
- Changes in sexual function.
- Receptors become less responsive with continuous use, which is why cycling matters.
- Long term at high doses: organ growth. In guinea pigs, Long R3 IGF-1 infusion significantly increased the weight of the gut, kidneys, adrenals, and spleen.
- Long term at high doses: intestinal enlargement, heart enlargement, and insulin resistance.
- Long term at high doses: irregular heartbeat, overabundant tissue growth especially in the face, and acromegalic cardiomyopathy — enlargement and weakening of the heart.
- Possible abnormal cell growth. A large meta-analysis of 17 prospective studies and over 10,000 prostate cancer cases found higher circulating IGF-1 was linked to higher prostate cancer risk, with an odds ratio of 1.29 for the highest versus lowest fifth. Similar links exist for breast and bowel cancer. That is not proof this peptide causes cancer, but chronically high IGF-1 is not risk-free.
- Hypoglycaemia is the most common and most dangerous acute effect: shakiness, tremor, sweating, confusion, impaired concentration, weakness, tachycardia. Fast-acting carbohydrate should always be available, with carbohydrate and protein consumed around the injection.
- Water retention and bloating, mild to moderate, driven by increased renal sodium reabsorption. Cosmetic and reversible on cessation; restricting fluid or sodium worsens it.
- Arthralgia and myalgia.
- Headache.
- Fatigue and lethargy during cycle.
- Nausea.
- Injection site reactions: swelling, redness, itching.
- Abdominal discomfort and bloating.
- Changes in sexual function.
- Receptor desensitisation with prolonged exposure via internalisation and degradation of the IGF-1 receptor — the mechanistic basis for mandatory cycling. Continuous use beyond 6 weeks also raises insulin resistance risk.
- Organ growth at high dose over extended periods: Long R3 IGF-1 infusion in guinea pigs significantly increased adrenal, gut, kidney, and spleen weights.
- Sustained supraphysiological IGF-1 carries intestinal hypertrophy, cardiac hypertrophy, and insulin resistance as primary long-term concerns, with attendant cardiovascular risk.
- High dose, long-term: cardiac arrhythmia, overabundant tissue growth (particularly facial), acromegalic cardiomyopathy.
- Proliferative risk: a meta-analysis pooling 17 prospective studies and over 10,000 prostate cancer cases reported an odds ratio of 1.29 for highest versus lowest fifth of circulating IGF-1, with similar positive associations for breast and colorectal cancer. Association, not causation, but chronically elevated IGF-1 is not without risk.
What the evidence shows
There are no published dose-finding studies for IGF-1 LR3 in healthy people using the injection protocols that are common in practice. Almost everything practical is worked out from research on natural IGF-1 plus the known chemical differences of the LR3 version.
A 2020 review (Yoshida and Delafontaine) confirmed that IGF-1 increases muscle protein building through the PI3K-Akt-mTOR pathway, suppresses muscle breakdown by blocking E3 ubiquitin ligases, and switches on satellite cells for muscle repair. It also noted IGF-1 signalling is suppressed in many chronic diseases, which contributes to muscle wasting.
A 1999 study (Barton-Davis et al.) showed roughly half of IGF-1's muscle-growth effect depends on satellite cells. Disabling those cells with radiation in mice cut the growth response about in half.
A 1994 study in healthy humans (Fryburg) infused IGF-1 into an artery and saw forearm muscle protein synthesis rise by 49 to 74 percent, protein breakdown fall by about 45 percent at higher doses, and blood flow increase by 75 to 213 percent.
A 1997 study in pigs and marmoset monkeys (Tomas et al.) compared IGF-1 variants that bind poorly to binding proteins, including LR3. They were 2 to 3 times more potent than natural IGF-1 at lowering blood sugar, with 4 to 8 times the cumulative effect over four hours.
A 1995 guinea pig study (Conlon et al.) found Long R3 IGF-1 infusion grew the adrenals, gut, kidneys, and spleen. That is the source of the organ-growth concern.
A 2026 rat study (Clark et al.) delivered IGF-1 LR3 in a hydrogel filler for volumetric muscle loss. Muscle weight rose at high doses, but function, fibre size, and fibre count did not improve. More IGF-1 does not automatically mean better muscle.
No published dose-finding studies exist for IGF-1 LR3 in healthy humans by subcutaneous or intramuscular routes. Animal work used infusion protocols, and the sole FDA-approved indication for native IGF-1 (Laron syndrome) is dosed differently from performance protocols. Mechanistic IGF-1 research is extensive; direct LR3 human research is extremely thin, and enhanced potency is inferred from binding-protein resistance.
Yoshida and Delafontaine (2020) reviewed IGF-1 regulation of skeletal muscle hypertrophy and atrophy: increased protein synthesis via PI3K-Akt-mTOR and PI3K-Akt-GSK3 beta, suppressed proteolysis through inhibition of E3 ubiquitin ligases driving proteasome-mediated degradation, and satellite cell activation for regeneration, with IGF-1 signalling suppressed across chronic disease states.
Barton-Davis et al. (1999) used gamma irradiation to ablate satellite cell function in mice and halved the IGF-1 hypertrophic response, establishing that approximately 50 percent of the effect is satellite-cell dependent.
Fryburg (1994), intra-arterial IGF-1 in healthy humans: forearm muscle protein synthesis up 49 to 74 percent, protein degradation down approximately 45 percent at higher doses, blood flow up 75 to 213 percent dose-dependently, with the author concluding IGF-1 exerts both GH-like and insulin-like actions on human muscle protein metabolism.
Tomas et al. (1997) in pigs and marmoset monkeys: IGF-1 variants with poor IGFBP affinity, including LR3-IGF-1, were 2 to 3 times more potent than native IGF-1 at lowering glucose and showed 4 to 8 times greater cumulative hypoglycaemic effect over four hours.
Conlon et al. (1995) in guinea pigs: Long R3 IGF-1 infusion significantly increased adrenal, gut, kidney, and spleen weight relative to controls — the direct basis of the organ-growth safety concern.
Clark et al. (2026): IGF-1 LR3 in a hydrogel void filler for volumetric muscle loss in rats increased muscle weight at high doses but produced no improvement in function, fibre size, or fibre count.
Arvat et al. (1997) underpins the negative-feedback argument against concurrent secretagogue use.
User reports
From public forums
None of this is published data. It is gathered from outside platforms including Reddit, bodybuilding forums, and peptide discussion groups, so treat it as anecdotal.
Most people report fuller muscles and better pumps in training within the first 1 to 2 weeks. Some early water retention is common, because IGF-1 LR3 makes the kidneys hold sodium and water follows. It is cosmetic and goes away after the cycle.
Visible changes in body composition and better recovery between sessions are usually reported around weeks 3 to 4. By the end of a 4 to 6 week cycle, users commonly report 3 to 8 pounds of lean tissue gain, and forum reports of 3 to 10 pounds at 40 to 80 mcg daily are common. Results vary a lot. People with lower body fat tend to notice changes sooner. Some users report dramatic results and others notice very little.
The side effects users mention most are mild water retention and bloating. Low blood sugar symptoms — shakiness, sweating, lightheadedness — come up often, especially when a dose is taken without enough carbohydrate. Joint pain and mild headaches are mentioned less often. Some people describe feeling lethargic and tired during the cycle.
A recurring theme is confusion over mixing. Many users start with bacteriostatic water and then learn the benzyl alcohol in it breaks the peptide down within 24 to 48 hours. The settled view is 0.6 percent acetic acid, which keeps it stable through the whole vial when refrigerated.
One honest caveat: the usual 40 to 80 mcg daily on a 4 to 6 week cycle has no direct clinical study behind it. It evolved through trial and error over decades.
Aggregated from external platforms including Reddit and bodybuilding forums; anecdotal, and not equivalent to published research.
Reported gains cluster at 3 to 10 pounds over a 4 to 6 week cycle at 40 to 80 mcg daily, with 3 to 8 pounds of lean tissue the more typical end-of-cycle figure. Higher doses reportedly yield more but with more pronounced side effects. The most consistent subjective signal is enhanced intramuscular fullness and pump within the first 1 to 2 weeks, with visible body composition change around weeks 3 to 4. Leaner users report noticing change sooner. Response variance is wide, from dramatic to negligible.
Early water retention is widely reported and attributed to increased renal sodium reabsorption; it is cosmetic and resolves off cycle.
Side effect reporting is dominated by mild water retention and bloating, followed by hypoglycaemic symptoms — shakiness, sweating, lightheadedness — particularly when dosing without adequate carbohydrate. Arthralgia and mild headache appear less frequently. Lethargy and fatigue during cycle are described by some users.
Reconstitution error is a recurring theme: users mixing with bacteriostatic water and learning that benzyl alcohol degrades the peptide within 24 to 48 hours. Experienced users use 0.6 percent acetic acid, stable through the full vial when refrigerated at 2 to 8 C.
Protocol divergence is explicit: 40 to 80 mcg subcutaneous or intramuscular daily on a 4 to 6 week cycle has no direct clinical study support and evolved through decades of trial and error in performance settings.
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
Do not run this at the same time as IGF-1 LR3. Raising IGF-1 directly makes the brain release somatostatin, which stops the pituitary answering the signals a secretagogue sends. Run them in sequence instead: 4 to 6 weeks of IGF-1 LR3, at least 2 to 3 days off to let the feedback reverse, then move to the secretagogue phase.
Contraindicated as a concurrent stack. Exogenous IGF-1 elevation triggers hypothalamic somatostatin release, blocking pituitary responsiveness; after exogenous GH injection, GHRH-pathway compounds were inhibited by 86 percent and ghrelin-pathway compounds blunted by about 32 percent. Sequence rather than combine: 4 to 6 weeks LR3, 2 to 3 days minimum washout to reverse negative feedback, then the secretagogue phase.
A GHRH-pathway compound, so the same rule applies — do not run it alongside IGF-1 LR3. Use it in a separate phase for visceral fat reduction once the IGF-1 LR3 cycle has ended.
GHRH analogue subject to the same somatostatin-mediated interference; concurrent use is counterproductive. Best positioned in a separate block, where its visceral adipose reduction complements a prior LR3 hypertrophy phase rather than overlapping it.
Another growth hormone booster that works through the pituitary. Running it with IGF-1 LR3 wastes both. Keep them in separate phases.
GHRH-pathway secretagogue inhibited by the same IGF-1-driven somatostatin feedback. Sequence, do not stack.
Works on a different signal to the GHRH compounds but is still blunted by high IGF-1. Use it after the IGF-1 LR3 cycle, not during.
Ghrelin-pathway secretagogue; blunted by roughly 32 percent under exogenous GH-induced feedback, less completely suppressed than GHRH analogues but still not worth running concurrently.
An oral growth hormone booster. Do not run it with IGF-1 LR3 — the raised IGF-1 blocks it from working. It also worsens insulin sensitivity while IGF-1 LR3 lowers blood sugar, so the glucose picture gets messy.
Orally active GHS subject to the same somatostatin interference, making concurrent use counterproductive. It also impairs insulin sensitivity while LR3 drives hypoglycaemia, compounding glycaemic instability. Run sequentially, based on goal.
- Testosterone replacement therapy
No interaction concerns. It can be run alongside IGF-1 LR3 without conflict — different pathways. Users report increased strength, better endurance, faster muscle gains, and shorter recovery times from the pairing.
No documented interaction; distinct pathways and mechanisms, so concurrent use is unproblematic. Reported outcomes from the pairing are increased strength, improved endurance, accelerated hypertrophy, and reduced recovery time.
No interaction concerns. It is a healing compound that works differently, so it can be run at the same time to support joints and soft tissue while you build muscle.
No direct interaction; operates through separate repair pathways and can be run concurrently. Relevant because tendon and connective tissue adaptation lags muscle adaptation when hypertrophy is this rapid.
Also a healing compound with no interaction concerns. Can be run at the same time for joint and soft tissue repair.
Grouped with BPC-157 as a repair compound operating on different pathways; concurrent use carries no documented conflict.
Supports fat loss during cutting phases and does not affect blood sugar.
Lipolysis support for cutting phases without glycaemic impact, so it does not compound the hypoglycaemia risk.
- Tirzepatide
A GLP-1 medicine. No known interactions, but both it and IGF-1 LR3 affect blood sugar, so check glucose more closely if using both.
No documented interactions with GLP-1 receptor agonists, but overlapping effects on glucose metabolism warrant closer glycaemic monitoring. The pairing is a metabolic-control measure, not an anabolic one.
- Insulin
Extremely dangerous with IGF-1 LR3. Both lower blood sugar by different routes and together they can cause severe, possibly fatal hypoglycaemia. Not recommended outside a highly supervised medical setting.
Combination is extremely dangerous. Additive glucose lowering through distinct mechanisms can produce severe, potentially fatal hypoglycaemia. Not recommended outside highly supervised medical settings.
Common questions
Why use IGF-1 LR3 instead of growth hormone secretagogues?
They are different tools for different goals. Secretagogues work inside your body's natural feedback system and keep the natural pulsing release of growth hormone intact, which matters for sleep and insulin sensitivity. That makes them better for general optimisation and longevity. IGF-1 LR3 skips all of that and lets you push IGF-1 above your natural ceiling. If the goal is optimisation, work upstream with secretagogues. If the context is performance and you understand the risks, IGF-1 LR3 is the more direct tool.
Secretagogues operate within endogenous feedback and preserve pulsatile GH release, which matters for sleep, insulin sensitivity, and any system dependent on rhythmic GH signalling — the better fit for optimisation and longevity. IGF-1 LR3 bypasses the pituitary and liver entirely, acting directly at the IGF-1 receptor and allowing supraphysiological IGF-1. That makes it more predictable but places it outside the feedback mechanisms that normally constrain the axis. Upstream for optimisation, direct for performance with risk accepted.
Should a TRT clinic be prescribing IGF-1 LR3 for optimisation?
For optimisation, there is no reason to inject IGF-1 directly. Your body already makes it — it just needs the right signal upstream. The correct order is to support your own production through the secretagogue route first, and if the pituitary does not respond, direct growth hormone is the next step. The only clinical situation where injecting IGF-1 makes sense is a very rare genetic condition where the liver cannot convert growth hormone into IGF-1. Clinics selling it for general optimisation are selling a high-priced peptide that creates more problems than it solves.
For optimisation there is no rationale for direct IGF-1 administration. Endogenous production exists and responds to upstream signalling, so the sequence is secretagogue support first, then exogenous GH if the pituitary fails to respond. The only clinically justified indication for direct IGF-1 is GH receptor insensitivity, where hepatic conversion of GH to IGF-1 cannot occur. Prescribing it for general optimisation substitutes an expensive peptide with a worse risk profile for the physiological route.
Why does IGF-1 LR3 need to be cycled?
Continuous exposure makes the receptors it acts on less responsive. They get pulled inside the cell and broken down, so the same dose does less over time. Continuing past 6 weeks also raises the risk of insulin resistance. The receptors recover during the time off. Sticking to 4 to 6 weeks on with equal time off, and a minimum of 4 weeks off, prevents this from becoming a problem.
Prolonged stimulation drives IGF-1 receptor downregulation via internalisation and degradation, reducing responsiveness. Continuous use beyond 6 weeks also increases insulin resistance risk. Receptor density recovers during the washout, so the standard pattern is 4 to 6 weeks on with at least 4 weeks off, and equal time off is the conservative default.
Can subcutaneous injection be used instead of intramuscular?
Yes. Injecting under the skin still gives you the whole-body benefit. Injecting into the trained muscle gives a higher local concentration at the target tissue, which some people prefer. You can alternate — under the skin on rest days, into the muscle on training days. There is no need to pick one and stick with it.
Yes. Subcutaneous administration retains full systemic benefit given the 20 to 30 hour activity window. Intramuscular injection into the trained muscle provides localised concentration at the target tissue, which some users prefer. Alternating routes — subcutaneous on rest days, intramuscular on training days — is acceptable; the route does not need to be fixed.
Why acetic acid instead of bacteriostatic water?
The benzyl alcohol preservative in bacteriostatic water breaks down the IGF-1 LR3 structure within 24 to 48 hours. A 0.6 percent acetic acid solution creates a mildly acidic environment that keeps the peptide stable for weeks when refrigerated at 2 to 8 C. Use the vial within 28 days.
Benzyl alcohol in bacteriostatic water degrades the IGF-1 LR3 peptide structure within 24 to 48 hours. A 0.6 percent acetic acid solution maintains the mildly acidic pH that supports structural stability through the full vial, refrigerated at 2 to 8 C, used within 28 days. This is the single most common reconstitution error reported.
Can IGF-1 LR3 be stacked with CJC-1295, Ipamorelin, or MK-677?
No. Raising IGF-1 directly makes the brain release somatostatin, which stops the pituitary responding to what the secretagogue is telling it to do. Research showed GHRH-pathway compounds were inhibited by 86 percent and ghrelin-pathway compounds blunted by about 32 percent after exogenous growth hormone injection. Running both means paying for both and getting meaningful output from neither. Pick one approach based on your goal, or run them in sequence.
No. Exogenous IGF-1 elevation triggers hypothalamic somatostatin release, which blocks pituitary responsiveness to secretagogue signalling. After exogenous GH injection, GHRH-pathway compounds (CJC-1295, Tesamorelin, Sermorelin) were inhibited by 86 percent and ghrelin-pathway compounds (Ipamorelin) blunted by about 32 percent. Concurrent use wastes both. Sequence instead: 4 to 6 weeks LR3, 2 to 3 days minimum to reverse the feedback, then the GH support phase.
What is the biggest acute risk and how is it managed?
Low blood sugar. IGF-1 LR3 has strong insulin-like effects and can drop glucose quickly. Always keep fast-acting carbohydrate within reach, and eat carbohydrate and protein shortly after injecting. Dosing within 15 to 30 minutes of training, with food, both reduces that risk and supports muscle growth. Never dose fasted, and never combine it with insulin.
Hypoglycaemia. The insulin-like actions can lower blood glucose significantly, producing shakiness, tremor, sweating, confusion, impaired concentration, weakness, and tachycardia. Fast-acting carbohydrate should always be on hand, with carbohydrate and protein consumed around the injection. Post-training dosing within 15 to 30 minutes both mitigates the risk and exploits elevated nutrient uptake. Fasted administration compounds the risk; insulin co-administration is potentially fatal.
How quickly do effects appear?
There is no published clinical data on timelines in healthy people using injection protocols, so this comes from user reports. Most report fuller muscles and better pumps in the first 1 to 2 weeks, along with some water retention. Visible body composition change and better recovery are usually reported around weeks 3 to 4. By the end of a 4 to 6 week cycle, users commonly report 3 to 8 pounds of lean tissue gain. Results vary a lot between individuals.
No published clinical data establishes timelines for injected IGF-1 LR3 in healthy humans; the following is anecdotal. Increased intramuscular fullness and training pumps are typically reported within 1 to 2 weeks, accompanied by early sodium-driven water retention. Body composition change and improved inter-session recovery are reported around weeks 3 to 4. End-of-cycle reports at 4 to 6 weeks cluster at 3 to 8 pounds of lean tissue, with forum ranges up to 10 pounds at 40 to 80 mcg daily. Individual variation is substantial.
References
- Yoshida T, Delafontaine P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells. 2020;9(9):1970.
- Barton-Davis ER, Shoturma DI, Sweeney HL. Contribution of satellite cells to IGF-I induced hypertrophy of skeletal muscle. Acta Physiologica Scandinavica. 1999;167(4):301-305.
- Fryburg DA. Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism. Am J Physiol. 1994;267(2 Pt 1):E331-6.
- Tomas FM, Walton PE, Dunshea FR, Ballard FJ. IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys. J Endocrinol. 1997;155(2):377-386.
- Conlon MA, Tomas FM, Owens PC, Wallace JC, Howarth GS, Ballard FJ. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol. 1995;146(2):247-253.
- Adams GR. Invited Review: Autocrine/paracrine IGF-I and skeletal muscle adaptation. J Appl Physiol. 2002;93(3):1159-1167.
- Florini JR, Ewton DZ, Coolican SA. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev. 1996;17(5):481-517.
- Arvat E, Di Vito L, Gianotti L, et al. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man. Metabolism. 1997;46(1):83-88.
- Clark AR, Adams AT, McKinley TO, Natoli RM, Dearth CL, Goldman SM. Provisional Treatment of Volumetric Muscle Loss With Insulin-like Growth Factor 1 Releasing Muscle Void Fillers. J Surg Res. 2026;317:461-466.
- Endocrine Factors in the Pathogenesis of Prostate Cancer Collaborative Group. A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. Cancer Res. 2016;76(8):2288-2300.
- Machida S, Booth FW. Insulin-like growth factor 1 and muscle growth: implication for satellite cell proliferation. Proc Nutr Soc. 2004;63(2):337-340.
This entry has been reviewed and expanded with additional reference material. Units are recomputed from the stated protocol.